Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.

Welliver RC, Papin JF, Preno A, Ivanov V, Tian JH, Lu H, Guebre-Xabier M, Flyer D, Massare MJ, Glenn G, Ellingsworth L, Smith G.

Vaccine. 2019 Nov 21. pii: S0264-410X(19)31510-5. doi: 10.1016/j.vaccine.2019.11.003. [Epub ahead of print]

PMID:
31761502
2.

Evaluation of transcutaneous immunization as a delivery route for an enterotoxigenic E. coli adhesin-based vaccine with CfaE, the colonization factor antigen 1 (CFA/I) tip adhesin.

Rollenhagen JE, Woods CM, O'Dowd A, Poole ST, Tian JH, Guebre-Xabier M, Ellingsworth L, Prouty MG, Glenn G, Savarino SJ.

Vaccine. 2019 Sep 30;37(42):6134-6138. doi: 10.1016/j.vaccine.2019.08.057. Epub 2019 Sep 3.

3.

Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.

Patel N, Massare MJ, Tian JH, Guebre-Xabier M, Lu H, Zhou H, Maynard E, Scott D, Ellingsworth L, Glenn G, Smith G.

Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12.

4.

Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.

Xie Q, Wang Z, Ni F, Chen X, Ma J, Patel N, Lu H, Liu Y, Tian JH, Flyer D, Massare MJ, Ellingsworth L, Glenn G, Smith G, Wang Q.

PLoS One. 2019 Feb 7;14(2):e0210749. doi: 10.1371/journal.pone.0210749. eCollection 2019.

5.

Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.

Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.

Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.

PMID:
30389195
6.

Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.

Smith G, Liu Y, Flyer D, Massare MJ, Zhou B, Patel N, Ellingsworth L, Lewis M, Cummings JF, Glenn G.

Vaccine. 2017 Sep 25;35(40):5366-5372. doi: 10.1016/j.vaccine.2017.08.021. Epub 2017 Aug 22.

7.

Transcutaneous immunization with Intercell's vaccine delivery system.

Seid RC Jr, Look JL, Ruiz C, Frolov V, Flyer D, Schafer J, Ellingsworth L.

Vaccine. 2012 Jun 19;30(29):4349-54. doi: 10.1016/j.vaccine.2011.09.113. Review.

PMID:
22682290
8.

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.

Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC.

Vaccine. 2012 Jun 13;30(28):4249-58. doi: 10.1016/j.vaccine.2012.04.045. Epub 2012 Apr 23.

PMID:
22537987
9.

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.

Vaccine. 2009 Dec 30;27 Suppl 6:G60-6. doi: 10.1016/j.vaccine.2009.10.031.

PMID:
20006142
10.

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

Frerichs DM, Ellingsworth LR, Frech SA, Flyer DC, Villar CP, Yu J, Glenn GM.

Vaccine. 2008 May 23;26(22):2782-7. doi: 10.1016/j.vaccine.2008.02.070. Epub 2008 Mar 28.

PMID:
18455283
11.

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch.

Frolov VG, Seid RC Jr, Odutayo O, Al-Khalili M, Yu J, Frolova OY, Vu H, Butler BA, Look JL, Ellingsworth LR, Glenn GM.

Influenza Other Respir Viruses. 2008 Mar;2(2):53-60. doi: 10.1111/j.1750-2659.2008.00040.x.

12.

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch.

Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, Yu J.

Expert Rev Vaccines. 2007 Oct;6(5):809-19. Review.

PMID:
17931160
13.

GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant.

Zoeteweij JP, Epperson DE, Porter JD, Zhang CX, Frolova OY, Constantinides AP, Fuhrmann SR, El-Amine M, Tian JH, Ellingsworth LR, Glenn GM.

J Immunol. 2006 Jul 15;177(2):1197-207.

14.

Induction of protective immunity against lethal anthrax challenge with a patch.

Kenney RT, Yu J, Guebre-Xabier M, Frech SA, Lambert A, Heller BA, Ellingsworth LR, Eyles JE, Williamson ED, Glenn GM.

J Infect Dis. 2004 Aug 15;190(4):774-82. Epub 2004 Jul 13.

PMID:
15272406
15.

Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice.

Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM.

J Virol. 2004 Jul;78(14):7610-8.

16.

Transcutaneous immunization and immunostimulant strategies.

Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR.

Immunol Allergy Clin North Am. 2003 Nov;23(4):787-813. Review.

PMID:
14753392
17.

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.

Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP.

Expert Rev Vaccines. 2003 Apr;2(2):253-67. Review.

PMID:
12899576
18.
19.

Transforming growth factor beta 1 systemically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice.

Carlino JA, Higley HR, Creson JR, Avis PD, Ogawa Y, Ellingsworth LR.

Exp Hematol. 1992 Sep;20(8):943-50.

PMID:
1505639
20.

Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism.

Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG.

Science. 1992 Jul 24;257(5069):545-8.

PMID:
1636092
21.

Differential modulation of transforming growth factor-beta 1 expression and mucin deposition by retinoic acid and sodium lauryl sulfate in human skin.

Fisher GJ, Tavakkol A, Griffiths CE, Elder JT, Zhang QY, Finkel L, Danielpour D, Glick AB, Higley H, Ellingsworth L, et al.

J Invest Dermatol. 1992 Jan;98(1):102-8.

22.

Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor.

Keller JR, Jacobsen SE, Sill KT, Ellingsworth LR, Ruscetti FW.

Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7190-4.

23.
24.

Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome.

Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UE, Mergenhagen SE, Orenstein JM.

J Exp Med. 1991 Apr 1;173(4):981-91.

25.

Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition.

Falk LA, De Benedetti F, Lohrey N, Birchenall-Roberts MC, Ellingsworth LW, Faltynek CR, Ruscetti FW.

Blood. 1991 Mar 15;77(6):1248-55.

PMID:
1848114
26.

A novel polyclonal antibody (CL-B1/29) for immunolocalization of transforming growth factor-beta 2 (TGF-beta 2) in adult mouse.

Ksander GA, Gerhardt CO, Dasch JR, Ellingsworth LR.

J Histochem Cytochem. 1990 Dec;38(12):1831-40.

PMID:
2254647
27.

Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives.

DeLustro F, Dasch J, Keefe J, Ellingsworth L.

Clin Orthop Relat Res. 1990 Nov;(260):263-79. Review.

PMID:
2225633
28.

Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor-beta-mediated autocrine negative loop by phorbol myristate acetate.

Sing GK, Ruscetti FW, Beckwith M, Keller JR, Ellingsworth L, Urba WJ, Longo DL.

Cell Growth Differ. 1990 Nov;1(11):549-57.

29.

Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium.

Wahl SM, Allen JB, Wong HL, Dougherty SF, Ellingsworth LR.

J Immunol. 1990 Oct 15;145(8):2514-9.

PMID:
2212650
30.
31.
32.

Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation.

Keller JR, Mcniece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, Ruscetti FW.

Blood. 1990 Feb 1;75(3):596-602.

PMID:
1967539
33.

Two forms of transforming growth factor-beta are equally potent selective growth inhibitors of early murine hematopoiesis.

Keller JR, Sing GK, Ellingsworth LR, Ruscetti SK, Ruscetti FW.

Ann N Y Acad Sci. 1990;593:172-80. No abstract available.

PMID:
2375594
34.

Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.

Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM.

J Exp Med. 1990 Jan 1;171(1):231-47.

35.

Transforming growth factor-beta 1 specifically localizes in elastin during synovial inflammation: an immunoelectron microscopic study.

Heine UI, Wahl SM, Munoz EF, Allen JB, Ellingsworth LR, Flanders KC, Roberts AB, Sporn MB.

Arch Geschwulstforsch. 1990;60(4):289-94.

PMID:
2167651
36.

Transforming growth factor-beta in psoriasis. Pathogenesis and therapy.

Elder JT, Ellingsworth LR, Fisher GJ, Voorhees JJ.

Ann N Y Acad Sci. 1990;593:218-30. No abstract available.

37.

Gamma-interferon-induced activation of latent transforming growth factor-beta by human monocytes.

Twardzik DR, Mikovits JA, Ranchalis JE, Purchio AF, Ellingsworth L, Ruscetti FW.

Ann N Y Acad Sci. 1990;593:276-84. No abstract available.

PMID:
2115757
38.
39.

Transforming growth factor-beta blocks proliferation but not early mitogenic signaling events in T-lymphocytes.

Morris DR, Kuepfer CA, Ellingsworth LR, Ogawa Y, Rabinovitch PS.

Exp Cell Res. 1989 Dec;185(2):529-34.

PMID:
2689199
40.

Response of bone marrow stromal cells to adipogenic antagonists.

Gimble JM, Dorheim MA, Cheng Q, Pekala P, Enerback S, Ellingsworth L, Kincade PW, Wang CS.

Mol Cell Biol. 1989 Nov;9(11):4587-95.

41.

Differential effects of TGF-beta 1 on lymphohemopoiesis in long-term bone marrow cultures.

Hayashi S, Gimble JM, Henley A, Ellingsworth LR, Kincade PW.

Blood. 1989 Oct;74(5):1711-7.

PMID:
2790195
43.

Normal B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor-beta.

Lee G, Namen AE, Gillis S, Ellingsworth LR, Kincade PW.

J Immunol. 1989 Jun 1;142(11):3875-83.

PMID:
2785567
44.

Transforming growth factor beta 1 (TGF-beta 1) receptor expression on resting and mitogen-activated T cells.

Ellingsworth L, Nakayama D, Dasch J, Segarini P, Carrillo P, Waegell W.

J Cell Biochem. 1989 Apr;39(4):489-500.

PMID:
2785999
45.
46.

Overexpression of transforming growth factor alpha in psoriatic epidermis.

Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ Jr, Ellingsworth L, Derynck R, Voorhees JJ.

Science. 1989 Feb 10;243(4892):811-4.

PMID:
2916128
47.
48.

Transforming growth factor beta: possible roles in the regulation of normal and leukemic hematopoietic cell growth.

Keller JR, Sing GK, Ellingsworth LR, Ruscetti FW.

J Cell Biochem. 1989 Feb;39(2):175-84. Review.

PMID:
2654150
49.

Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice.

Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB.

J Cell Biol. 1989 Feb;108(2):661-9.

50.

Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes.

Flanders KC, Thompson NL, Cissel DS, Van Obberghen-Schilling E, Baker CC, Kass ME, Ellingsworth LR, Roberts AB, Sporn MB.

J Cell Biol. 1989 Feb;108(2):653-60.

Supplemental Content

Loading ...
Support Center